Thanks for alerting us arou011.
A good interpretation of the results.
I particularly like their year on year valuations... $5 wouldn't hurt ;)
One point I'm not so sure about is their assumption of first sales in Australia occurring in 2014.
This would precede Phase 3 primary endpoints, so do they believe CVac will be fast tracked by the TGA?
Or are they presuming revenue from compassionate use?
interim data from can-003 clinical trial, page-28
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $845.3K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 140318 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 14222 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |